Search for: "Mylan, Inc." Results 1 - 20 of 665
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Dec 2008, 5:31 am
By Mark Chael -- On December 2nd, Mylan, Inc. and Mylan Pharmaceuticals, Inc. announced that they had settled their dispute with Novartis Pharmaceuticals Corp., Novartis Corp., and Novartis International AG over a generic version of Novartis' Femara ® tablets.According to the press release, Femara ® tablets, which are used in the treatment of breast cancer, had U.S. sales of about $470 million for the 12 months ending September 30, 2008.… [read post]
17 Dec 2008, 5:54 am
The challenges to the '777 patent had been initiated by Defendants-Appellants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., and UDL Laboratories, Inc. [read post]
9 Jan 2020, 8:25 pm by Brianna Smith
Mylan Pharmaceuticals Inc. is recalling certain batches of its Nizatidine Capsules, USP, over concerns they may contain a carcinogen. [read post]
10 Jun 2009, 9:02 pm
Seeking approval to market a generic version of levofloxacin, Defendants-Appellants Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA. [read post]
5 Apr 2020, 9:57 pm by Patent Docs
Mylan Pharmaceuticals Inc., the Federal Circuit reversed a decision by the U.S. [read post]
6 Sep 2016, 3:36 pm by Cynthia Marcotte Stamer
Schneiderman comes as Mylan is part of the widening backlash against Mylan's in response to its sharp increase in the price of the EpiPen, treatments for life-threatening anaphylactic shock. [read post]
14 Feb 2019, 9:50 pm by Patent Docs
RE38,551 challenged in inter partes review were not unpatentable for obviousness, in Mylan Pharmaceuticals Inc. v. [read post]
20 Aug 2017, 7:14 am by Gregory J. Brod
Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. agree to pay $465 million to settle a lawsuit brought under the False Claims Act (FCA). [read post]
8 Dec 2021, 8:52 am by Lawrence B. Ebert
The outcome AstraZeneca AB and AstraZeneca Pharmaceuticals LP (collectively, “AstraZeneca”) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
22 Jul 2018, 8:32 pm by Patent Docs
IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132 (and parallel IPRs filed by Petitioners Teva Pharmaceuticals USA, Inc. and Akorn, Inc., which had... [read post]
5 Oct 2022, 8:12 pm by Patent Docs
Patent No. 7,326,708 were either anticipated or rendered obvious by the asserted prior art, in Mylan Pharmaceuticals Inc. v. [read post]
19 Oct 2016, 8:28 am by Susanna Leighton
Department of Justice (DOJ) to reject the proposed $465 million settlement reached between the government and Mylan, Inc. after it was discovered the beleaguered corporation, responsible for increasing the price of the life-saving EpiPen to $600 per 2-pak in August of this The post DOJ Urged to Reject Mylan Settlement by Senator appeared first on Legal Reader. [read post]
11 Oct 2016, 12:22 pm by Susanna Leighton
EpiPen maker Mylan, Inc. has been ripping off Medicare and Medicaid for years but is only now being held accountable for their unethical, unprofessional and deceitful practices; the company has agreed to pay the government $465 million for having overcharged both insurance providers by classifying their drug as “generic,” thus reducing their percentage of the The post Mylan to Pay $465 Million for Overcharging Medicaid appeared first on Legal Reader. [read post]
31 Dec 2010, 3:57 am by Bob Kraft
The  drug maker Mylan Inc. has agreed to settle a lawsuit brought against it by both the U.S. government and the State of Texas. [read post]
8 Nov 2021, 9:15 am by Steve Brachmann
Mylan Pharmaceuticals Inc. affirming a ruling of the District of Delaware, which dismissed a Hatch-Waxman lawsuit against related Mylan entities for either improper venue or failure to state a claim upon which relief could be granted. [read post]
18 Oct 2009, 5:42 pm
Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the [...] [read post]